# US 2018/0021432 A1 · Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021432 A1
- Document ID: US20180021432A1
- Status: Published application
- Kind: A1
- Application number: 15/655,394
- Filed: 2017-07-20
- Published: 2018-01-25
- Earliest claimed: 2016-07-20
- Assignees: Hybrigenics
- Applicants: Hybrigenics SA.
- Inventors: Susan BENJAMIN; Cécile PLANQUETTE; Rémi DELANSORNE
- Web page: https://patentgrep.com/patent/US20180021432A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/30: from tumour cells
- C07K 16/3061: {Blood cells}
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.

## Claims

### Claim 1

A combination of inecalcitol with an anti-CD38 agent.

### Claim 2 (depends on 1)

The combination according to claim 1 wherein the anti-CD38 agent is an anti-CD38 antibody, or a single chain or fragment thereof capable of binding to CD38.

### Claim 3 (depends on 1)

The combination according to claim 1 wherein said anti-CD38 agent is daratumumab, isatuximab or MOR202.

### Claim 4

A combination of an anti-CD38 agent with inecalcitol for use for the treatment of cancer.

### Claim 5 (depends on 4)

The combination for use according to claim 4, wherein inecalcitol and the anti-CD38 agent are administered simultaneously, separately, sequentially or spread-over-time, in any order.

### Claim 6 (depends on 4)

The combination for use according to claim 4, wherein said cancer is an hematological malignancy.

### Claim 7 (depends on 4)

The combination for use according to claim 4, wherein said cancer is a CD38-positive hematological malignancy.

### Claim 8 (depends on 4)

The combination for use according to claim 4, wherein said cancer is multiple myeloma.

### Claim 9 (depends on 4)

The combination for use according to claim 4, wherein said cancer is classical Hodgkin lymphoma.

### Claim 10 (depends on 4)

The combination for use according to claim 4, wherein said cancer is B-acute lymphoblastic leukemia.

### Claim 11 (depends on 4)

The combination for use according to claim 4, wherein said cancer is a CD38-negative hematological malignancy.

### Claim 12 (depends on 4)

The combination for use according to claim 4, wherein said cancer is acute myeloid leukemia.

### Claim 13 (depends on 4)

The combination for use according to claim 4, wherein inecalcitol transforms the CD38-negative malignancy into an CD38-positive malignancy, thus amenable to further treatment with said anti-CD38 agent.

### Claim 14 (depends on 4)

The combination for use according to claim 4, wherein the anti-CD38 agent is an anti-CD38 antibody, or a single chain or fragment thereof capable of binding to CD38.

### Claim 15 (depends on 4)

The combination for use according to claim 4, wherein said anti-CD38 agent is daratumumab, isatuximab or MOR202.

### Claim 16

Inecalcitol for use for increasing the clinical response to an anti-CD38 agent in a patient suffering from cancer.

### Claim 17 (depends on 16)

The Inecalcitol for use according to claim 16, wherein the cancer is selected from the group consisting of a hematological malignancy, a CD38-positive hematological malignancy, a multiple myeloma, a Hodgkin lymphoma, B-acute lymphoblastic leukemia, a CD38-negative hematological malignancy, and an acute myeloid leukemia and/or said anti-CD38 agent is selected from the group consisting of:
an anti-CD38 antibody, a single chain or fragment thereof capable of binding to CD38,
daratumumab,
isatuximab and
MOR202.
